ES2684268T3 - Inhibidores de pirimidinil tirosina quinasa - Google Patents
Inhibidores de pirimidinil tirosina quinasa Download PDFInfo
- Publication number
- ES2684268T3 ES2684268T3 ES13800042.7T ES13800042T ES2684268T3 ES 2684268 T3 ES2684268 T3 ES 2684268T3 ES 13800042 T ES13800042 T ES 13800042T ES 2684268 T3 ES2684268 T3 ES 2684268T3
- Authority
- ES
- Spain
- Prior art keywords
- optionally substituted
- nitrogen
- equiv
- mmol
- membered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
Abstract
Un compuesto de fórmula I:**Fórmula** o una sal farmacéuticamente aceptable de este, en donde: cada R1 es independientemente hidrógeno, un grupo alifático C1-6 opcionalmente sustituido, un grupo heterocíclico monocíclico, de 3-7 miembros, opcionalmente sustituido, o un grupo heterociclilalquilo opcionalmente sustituido que tiene 3-7 átomos de carbono y 1-3 heteroátomos seleccionados independientemente de nitrógeno, oxígeno o azufre; o dos grupos R1 se toman junto con sus átomos interventores para formar un anillo heterocíclico monocíclico, saturado o parcialmente insaturado, de 3-7 miembros, opcionalmente sustituido que tiene 1-2 heteroátomos seleccionados independientemente de nitrógeno, oxígeno o azufre; en donde los grupos opcionalmente sustituidos pueden sustituirse con halógeno, -NO2, -CN, -OR, -SR, -N(R) 2, -C(O)R, -CO2 R, -N(R)C(O)OR, -C(O)N(R) 2, -OC(O)R, -N(R)C(O)R, -S(O)R, -S(O) 2 R, o -S(O) 2 N(R) 2; cada R es independientemente hidrógeno o un grupo alifático C1-6; o dos grupos R unidos al mismo nitrógeno se toman junto con sus átomos interventores para formar un anillo heterocíclico monocíclico, saturado o parcialmente insaturado, de 3-7 miembros, opcionalmente sustituido que tiene 1-2 heteroátomos, en donde cualquier segundo heteroátomo se selecciona independientemente de nitrógeno, oxígeno o azufre; El anillo A es**Fórmula** R2 es -Cl o -F; y R3 es -CF3, -OCF3, o -F.
Description
Los compuestos de la invención se sintetizan mediante una combinación adecuada de métodos sintéticos generalmente bien conocidos. Las técnicas útiles para sintetizar los compuestos de la invención son muy evidentes y accesibles para los expertos en la materia relevante. El análisis más adelante se ofrece para ilustrar algunos de los diversos métodos disponibles para usar en la obtención de los compuestos de la invención. Sin embargo, el análisis no está destinado a definir el alcance de las reacciones o las secuencias de reacciones que son útiles para preparar los compuestos de la presente invención.
Los compuestos de fórmula I pueden prepararse generalmente de acuerdo con el esquema 1.
8
10
otros métodos conocidos por un experto en la técnica, pueden aplicarse a todos los compuestos y subclases y especies de cada uno de estos compuestos, como se describe en la presente. Ejemplo 1 Síntesis de (3'R,4'S)-1'-terc-butil 4'-etil 2-oxo-[1,3'-bipiperidina]-1',4'-dicarboxilato
R: 98 % CH3OH, ta, 16 h tolueno, reflujo, 16 h
R: 86 % R: 88 %
R: 46 % R: 73 % ta, 2 h
R: 80 %
R: 92 %
THF, reflujo, 4 h
R: 88 %
Preparación del intermediario 3-oxopiperidina-4-carboxilato de etilo. El 1-bencil-3-oxopiperidina-4-carboxilato de etilo
10 1 (15,0 g, 50,5 mmol, 1,0 equiv) se hidrogenó en presencia del catalizador Pd/C 10 % (1,5 g) en H2 a presión atmosférica en MeOH (250 ml) durante 16 horas. El catalizador se filtró y el disolvente se concentró al vacío para producir 3-oxopiperidina-4-carboxilato de etilo 2 como un sólido de color amarillo claro (10,2 g, rendimiento: 98,0 %). ESI-MS (M+H)+: 172,1.1H NMR (400 MHz, DMSO-d6)δ:4,23 (q, 2H), 3,75 (s, 2H), 3,37 (s, 2H), 3,20-3,16 (m, 2H), 2,44 (t, 1H), 1,25 (t, 3H).
15 Preparación de 1-terc-butil 4-etil 3-oxopiperidina-1,4-dicarboxilato. El 3-oxopiperidina-4-carboxilato de etilo 2 (10,2 g, 60,0 mmol, 1,0 equiv) se disolvió en MeOH seco (200 ml) y se añadió Et3N (33,1 ml, 240 mmol, 4,0 equiv). La mezcla se agitó durante 1 hora y se añadió Boc2O (19,5 g, 90,0 mmol, 1,5 equiv) y se agitó durante 16 horas. El disolvente se concentró al vacío y el crudo se purificó mediante cromatografía en columna (sílice, éter de
20 petróleo/EtOAc =9:1) para producir el aceite amarillo claro 1-terc-butil 4-etil 3-oxopiperidina-1,4-dicarboxilato 3 (11,5 g, rendimiento: 86 %). ESI-MS (M+H-56)+: 216,0.1H NMR (400 MHz, CDCl3)δ:4,24 (q, 2H), 4,03 (s, 2H), 3,49 (t, 2H), 2,33 (t, 2H), 1,47 (s, 9H), 1,31 (t, 3H).
Preparación de (S)-1-terc-butil 4-etil 3-((1-feniletil)amino)-5,6-dihidro piridina-1,4-(2H)-dicarboxilato. En un matraz
25 seco equipado con una trampa de Dean-Stark y un condensador de reflujo, se disolvió 1-terc-butil 4-etil 3oxopiperidina-1,4-dicarboxilato 3 (10,0 g, 37,0 mmol, 1,1 equiv) en tolueno (100 ml). Se añadieron S-(-)-αmetilbenzilamina (4,9 g, 40,5 mmol, 1,1 equiv) y ácido p-toluenosulfónico monohidrato (0,7 g, 3,7 mmol, 0,1 equiv) y
20
5
10
15
20
25
30
Síntesis de trans-1'-terc-butil-4'-etil-3-yodo-2-oxo-[1,3'-bipiperidina]-1',4'-dicarboxilato. A la solución de trans-1'-tercbutil 4'-etil 2-oxo-[1,3'-bipiperidina]-1',4'-dicarboxilato 8 (141 mg, 2,58 mmol, 1,0 equiv) en tolueno seco (10 ml) a 0 °C, se añadieron sucesivamente TMEDA (0,89 g, 7,7 mmol, 3,0 equiv) y TMSCl (0,6 mg, 1,0 mmol, 2,0 equiv) en N2. Después de 0,5 horas, se añadió cuidadosamente I2 (0,98 g, 3,87 mmol, 1,5 equiv) en porciones pequeñas. La solución de reacción se agitó a 0 °C a temperatura ambiente durante 16 horas. La mezcla se diluyó con EtOAc (100 ml), se lavó con Na2S2O3 saturado (20 ml × 2) y salmuera (20 ml), se secó (Na2SO4), filtró y concentró al vacío. El producto crudo 9 (2,2 g, Y: 81 %) se usó directamente en la siguiente etapa sin purificación adicional. ESI-MS (M+H56)+: 424,9.1H NMR (400 MHz, CDCl3)δ: 4,78-4,73 (m, 1H), 4,19-4,04 (m, 4H), 3,55-3,30 (m, 4H), 3,24-3,16 (m, 2H), 2,73-2,60 (m, 1H), 2,22-2,14 (m, 2H), 1,96-1,78 (m, 2H), 1,70-1,60 (m, 1H),1,44 (s, 9H), 1,25 (t,J=7,2 Hz, 3H).
Síntesis de trans-1'-terc-butil 4'-etil 3-((3-cloro-5-(trifluorometil) fenil)amino)-2-oxo-[1,3'-bipiperidina]-1',4'dicarboxilato. Una solución 1,0 M de bis(trimetildisilil)amida de litio en THF (13 ml, 12 mmol, 2,0 equiv) se añadió mediante un embudo de adición a 10-15 °C a una solución de 3-cloro-5-(trifluorometil)anilina (15 g, 78 mmol, 1,2 equiv) en THF (13 ml). La mezcla se agitó a temperatura ambiente durante 20 min y se añadió una solución de trans1'-terc-butil-4'-etil-3-yodo-2-oxo-[1,3'-bipiperidina]-1',4'- dicarboxilato crudo 9 (3,7 g, 65 mmol, 1,0 equiv) en THF (13 ml) mediante un embudo de adición a 10-15 °C durante 30 min. Después de la adición, la reacción se agitó a la temperatura durante 30 min. Al terminar, la reacción se enfrió a 5 °C y se inactivó lentamente con agua (10 ml), manteniendo la temperatura por debajo de 20 °C. La reacción inactivada se extrajo con EtOAc (2 x 30 ml). Las capas orgánicas combinadas se lavaron con salmuera saturada (30 ml), se secaron (Na2SO4), filtraron y concentraron al vacío. El producto crudo resultante se purificó sobre gel de sílice eluyendo con un gradiente de 10 % a 75 % de EtOAc en heptanos para producir el producto deseado 10. ESI-MS (M+H-56)+: 463,1.1H NMR (400 MHz, CDCl3)δ:6,92 (s, 1H), 6,71-6,69 (m, 2H), 4,17-4,06 (m, 4H), 3,78-3,68 (m, 2H), 3,46-3,36 (m, 3H), 3,23-3,07 (m, 2H), 2,73-2,65 (m, 1H), 2,44-2,37 (m, 1H), 2,03-1,85 (m, 3H), 1,71-1,61 (m, 2H), 1,46 (s, 9H), 1,27-1,19 (m, 3H).
Síntesis del ácido trans-1'-(terc -butoxicarbonil)-3-((3-cloro-5-(trifluorometil) fenil) amino) -2-oxo-[1,3'-bipiperidina]-4'carboxílico. A una solución de trans-1'-terc-butil 4'-etil 3-((3-cloro-5-(trifluorometil)fenil)amino)-2-oxo-[1,3'bipiperidina]-1',4'-dicarboxilato 10 (180 mg, 0,33 mmol, 1,0 equiv) en EtOH (5 ml) se añadió NaOH (40 mg, 0,99 mmol, 3,0 equiv) y la solución se agitó a 80 °C durante 1 hora. El disolvente se concentró al vacío y el residuo se suspendió en agua (10 ml) y se ajustó a pH = 6 con HCl (4 N). El precipitado se filtró para producir el ácido (trans)-1'(terc-butoxicarbonil)-3-((3-cloro-5-(trifluorometil)fenil)amino)-2-oxo-[1,3'-bipiperidina]-4'-carboxílico 11 (150 mg, Y: 82 %) como un sólido amarillo que se usó en la próxima etapa sin purificación adicional. ESI-MS (M+H-85)+: 463,1.1H
22
Claims (1)
-
imagen1 imagen2 imagen3 imagen4
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261657360P | 2012-06-08 | 2012-06-08 | |
US201261657360P | 2012-06-08 | ||
PCT/US2013/044800 WO2013185084A1 (en) | 2012-06-08 | 2013-06-07 | Pyrimidinyl tyrosine kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2684268T3 true ES2684268T3 (es) | 2018-10-02 |
Family
ID=49712704
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES13800042.7T Active ES2684268T3 (es) | 2012-06-08 | 2013-06-07 | Inhibidores de pirimidinil tirosina quinasa |
ES18171833T Active ES2834333T3 (es) | 2012-06-08 | 2013-06-07 | Inhibidores pirimidinil de tirosina quinasa |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES18171833T Active ES2834333T3 (es) | 2012-06-08 | 2013-06-07 | Inhibidores pirimidinil de tirosina quinasa |
Country Status (30)
Country | Link |
---|---|
US (5) | US9394277B2 (es) |
EP (3) | EP2858499B1 (es) |
JP (6) | JP6214643B2 (es) |
KR (4) | KR20220154850A (es) |
CN (3) | CN113549055A (es) |
AR (1) | AR091273A1 (es) |
AU (5) | AU2013271407B2 (es) |
BR (2) | BR122021002178B1 (es) |
CA (2) | CA3108186A1 (es) |
CY (1) | CY1120638T1 (es) |
DK (1) | DK2858499T3 (es) |
EA (2) | EA027823B1 (es) |
ES (2) | ES2684268T3 (es) |
HK (1) | HK1209284A1 (es) |
HR (1) | HRP20181294T1 (es) |
HU (1) | HUE039897T2 (es) |
IL (2) | IL235938B (es) |
IN (1) | IN2014DN10576A (es) |
LT (1) | LT2858499T (es) |
MX (2) | MX363672B (es) |
NZ (1) | NZ702715A (es) |
PH (2) | PH12014502699B1 (es) |
PL (1) | PL2858499T3 (es) |
PT (1) | PT2858499T (es) |
RS (1) | RS57978B1 (es) |
SG (2) | SG11201408173WA (es) |
SI (1) | SI2858499T1 (es) |
TW (3) | TWI792158B (es) |
WO (1) | WO2013185084A1 (es) |
ZA (1) | ZA201409255B (es) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2473049T3 (en) | 2009-09-04 | 2019-04-01 | Biogen Ma Inc | INHIBITORS OF BRUTON'S TYROSINKINASE |
EP2632898A4 (en) | 2010-10-29 | 2014-04-02 | Biogen Idec Inc | HETEROCYCLIC TYROSINE KINASE HEMMER |
AR091273A1 (es) | 2012-06-08 | 2015-01-21 | Biogen Idec Inc | Inhibidores de pirimidinil tirosina quinasa |
WO2013185082A2 (en) | 2012-06-08 | 2013-12-12 | Biogen Idec Ma Inc. | Inhibitors of bruton's tyrosine kinase |
JP6431914B2 (ja) * | 2013-12-11 | 2018-11-28 | バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. | 腫瘍学、神経学及び免疫学におけるヒト疾患の治療に有用なビアリール化合物 |
WO2015151006A1 (en) | 2014-03-29 | 2015-10-08 | Lupin Limited | Substituted purine compounds as btk inhibitors |
WO2015170266A1 (en) | 2014-05-07 | 2015-11-12 | Lupin Limited | Substituted pyrimidine compounds as btk inhibitors |
SG10201903578VA (en) | 2014-10-24 | 2019-05-30 | Bristol Myers Squibb Co | Indole carboxamides compounds useful as kinase inhibitors |
BR112019001158A2 (pt) | 2016-07-21 | 2019-04-30 | Biogen Ma, Inc. | formas de succinato e composições de inibidores da tirosina quinase de bruton |
US20210113568A1 (en) | 2018-04-27 | 2021-04-22 | Ono Pharmaceutical Co., Ltd. | PREVENTIVE AND/OR THERAPEUTIC AGENT FOR AUTOIMMUNE DISEASE COMPRISING COMPOUND HAVING Btk INHIBITORY ACTIVITY AS ACTIVE INGREDIENT |
CA3108065A1 (en) | 2018-07-31 | 2020-02-06 | Loxo Oncology, Inc. | Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1h-pyrazole-4-carboxamide |
AU2020242287A1 (en) | 2019-03-21 | 2021-09-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A Dbait molecule in combination with kinase inhibitor for the treatment of cancer |
WO2021089791A1 (en) | 2019-11-08 | 2021-05-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
US20240100172A1 (en) | 2020-12-21 | 2024-03-28 | Hangzhou Jijing Pharmaceutical Technology Limited | Methods and compounds for targeted autophagy |
WO2022212893A1 (en) | 2021-04-02 | 2022-10-06 | Biogen Ma Inc. | Combination treatment methods of multiple sclerosis |
WO2023081709A1 (en) | 2021-11-03 | 2023-05-11 | Viracta Therapeutics, Inc. | Vecabrutinib for the treatment of graft-versus-host disease |
WO2023081715A1 (en) | 2021-11-03 | 2023-05-11 | Viracta Therapeutics, Inc. | Combination of car t-cell therapy with btk inhibitors and methods of use thereof |
WO2023110970A1 (en) | 2021-12-14 | 2023-06-22 | Netherlands Translational Research Center Holding B.V | Macrocyclic btk inhibitors |
Family Cites Families (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1624A (en) * | 1840-06-10 | Cooking-stove | ||
US4528138A (en) | 1984-06-20 | 1985-07-09 | E. R. Squibb & Sons, Inc. | 16-Keto-17-substituted thia-17-alkyl(or alkenyl or alkynyl) androstenes |
US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
FR2588189B1 (fr) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
DE69212850T2 (de) | 1991-01-15 | 1997-03-06 | Alcon Lab Inc | Verwendung von Karrageenan in topischen ophthalmologischen Zusammensetzungen |
US5212162A (en) | 1991-03-27 | 1993-05-18 | Alcon Laboratories, Inc. | Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
PA8474101A1 (es) | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | Compuestos de pirrolo [2,3-d] pirimidina |
US6919178B2 (en) | 2000-11-21 | 2005-07-19 | Sunesis Pharmaceuticals, Inc. | Extended tethering approach for rapid identification of ligands |
CN1481377A (zh) | 2000-03-17 | 2004-03-10 | ����˹�ж�-����˹˹����ҩƷ��˾ | 作为基质金属蛋白酶和TNF-α的抑制剂的环β-氨基酸衍生物 |
MY137020A (en) | 2000-04-27 | 2008-12-31 | Abbott Lab | Diazabicyclic central nervous system active agents |
CZ20023993A3 (cs) | 2000-06-26 | 2004-02-18 | Pfizer Products Inc. | Pyrolo [2,3-d]pyrimidinové sloučeniny jako imunosupresivní činidla |
PE20020507A1 (es) * | 2000-10-17 | 2002-06-25 | Schering Corp | Compuestos no-imidazoles como antagonistas del receptor histamina h3 |
WO2003037271A2 (en) * | 2001-10-30 | 2003-05-08 | Millennium Pharmaceuticals,Inc. | Compounds, pharmaceutical compositions and methods of use therefor |
CA2464934A1 (en) | 2001-10-31 | 2003-05-08 | Bayer Healthcare Ag | Pyrimido [4,5-b] indole derivatives |
EP1599468B1 (en) | 2003-01-14 | 2007-10-03 | Arena Pharmaceuticals, Inc. | 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia |
EP1678166B1 (en) | 2003-10-14 | 2009-07-29 | The Arizona Board of Regents on Behalf of the University of Arizona | Protein kinase inhibitors |
EP1778298A4 (en) * | 2004-04-01 | 2010-03-31 | Univ Pennsylvania | LIPOPROTEIN-NANO PLATFORMS |
WO2005117909A2 (en) | 2004-04-23 | 2005-12-15 | Exelixis, Inc. | Kinase modulators and methods of use |
FR2870541B1 (fr) | 2004-05-18 | 2006-07-14 | Proskelia Sas | Derives de pyrimidines antigonistes du recepteur de la vitronectine |
TW200621760A (en) | 2004-09-09 | 2006-07-01 | Mitsubishi Pharma Corp | 2-morpholino-4-pyrimidone compound |
AU2005304784B2 (en) * | 2004-11-04 | 2011-03-24 | Vertex Pharmaceuticals Incorporated | Pyrazolo[1,5-a]pyrimidines useful as inhibitors of protein kinases |
JP5254620B2 (ja) | 2004-12-03 | 2013-08-07 | メルク・シャープ・アンド・ドーム・コーポレーション | Cb1アンタゴニストとしての置換ピペラジン |
EP1848719B1 (en) | 2004-12-28 | 2012-02-01 | Exelixis, Inc. | [1h-pyrazolo[3,4-d]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-threonine kinase modulators (p70s6k, atk1 and atk2) for the treatment of immunological, inflammatory and proliferative diseases |
WO2006071875A1 (en) | 2004-12-29 | 2006-07-06 | Millennium Pharmaceuticals, Inc. | Compounds useful as chemokine receptor antagonists |
US7423043B2 (en) | 2005-02-18 | 2008-09-09 | Lexicon Pharmaceuticals, Inc. | 4-Piperidin-1-yl-7H-pyrrolo[2,3-d]pyrimidine compounds |
US20060281700A1 (en) | 2005-06-10 | 2006-12-14 | Baumann Christian A | Synergistic modulation of flt3 kinase using aminopyrimidines kinase modulators |
US20060281764A1 (en) | 2005-06-10 | 2006-12-14 | Gaul Michael D | Aminopyrimidines as kinase modulators |
TW200740779A (en) | 2005-07-22 | 2007-11-01 | Mitsubishi Pharma Corp | Intermediate compound for synthesizing pharmaceutical agent and production method thereof |
BR122021011787B1 (pt) | 2005-11-01 | 2022-01-25 | Impact Biomedicines, Inc | Inibidores de biaril meta pirimidina de cinases, composição farmacêutica e processo para preparar uma composição farmacêutica |
EP1965862A2 (en) * | 2005-12-21 | 2008-09-10 | Schering Corporation | Combination of an h3 antagonist/inverse agonist and an appetite suppressant |
WO2008005368A2 (en) | 2006-06-30 | 2008-01-10 | Abbott Laboratories | Piperazines as p2x7 antagonists |
WO2008012635A2 (en) | 2006-07-26 | 2008-01-31 | Pfizer Products Inc. | Amine derivatives useful as anticancer agents |
US20090325948A1 (en) | 2006-07-26 | 2009-12-31 | Timothy Brian Hurley | Inhibitors of undecaprenyl pyrophosphate synthase |
US20100160292A1 (en) | 2006-09-11 | 2010-06-24 | Cgi Pharmaceuticals, Inc | Kinase Inhibitors, and Methods of Using and Identifying Kinase Inhibitors |
KR101315610B1 (ko) * | 2006-09-22 | 2013-10-10 | 파마시클릭스, 인코포레이티드 | 브루톤 티로신 키나제 억제제 |
TW200840571A (en) * | 2007-03-02 | 2008-10-16 | Schering Corp | Piperidine derivatives and methods of use thereof |
JP2010522241A (ja) | 2007-03-21 | 2010-07-01 | ブリストル−マイヤーズ スクイブ カンパニー | 増殖性疾患、アレルギー性疾患、自己免疫疾患または炎症性疾患として有用な縮合ヘテロ環化合物 |
WO2008144253A1 (en) | 2007-05-14 | 2008-11-27 | Irm Llc | Protein kinase inhibitors and methods for using thereof |
BRPI0811898A2 (pt) | 2007-06-01 | 2019-09-24 | Glaxosmithkline Llc | composto, composição farmacêutica, métodos para tratar um neoplasma suscetível e um câncer em um mamífero, processo para preparar um composto, e, uso de um composto. |
SI2242749T1 (sl) * | 2008-02-05 | 2013-07-31 | F.Hoffmann-La Roche Ag | Novi piridinoni in piridazinoni |
JP2011519049A (ja) | 2008-04-29 | 2011-06-30 | イミューンエクサイト インコーポレイテッド | 免疫調節組成物およびその使用方法 |
ES2660418T3 (es) | 2008-07-16 | 2018-03-22 | Pharmacyclics Llc | Inhibidores de la tirosina quinasa de Bruton para el tratamiento de tumores sólidos |
WO2010068788A1 (en) * | 2008-12-10 | 2010-06-17 | Cgi Pharmaceuticals, Inc. | Heterocyclic amides as btk inhibitors |
WO2010080481A1 (en) * | 2008-12-19 | 2010-07-15 | Bristol-Myers Squibb Company | Carbazole carboxamide compounds useful as kinase inhibitors |
US9266890B2 (en) * | 2009-01-06 | 2016-02-23 | Dana-Farber Cancer Institute, Inc. | Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders |
US9096610B2 (en) | 2009-05-25 | 2015-08-04 | Sandoz Ag | Method for the production of ceftobiprole medocaril |
DK2473049T3 (en) | 2009-09-04 | 2019-04-01 | Biogen Ma Inc | INHIBITORS OF BRUTON'S TYROSINKINASE |
WO2011029043A1 (en) | 2009-09-04 | 2011-03-10 | Biogen Idec Ma Inc. | Heteroaryl btk inhibitors |
US8685880B2 (en) * | 2010-06-30 | 2014-04-01 | Chevron U.S.A. Inc. | On-site drying of aqueous salt for ionic liquid make-up |
EP2632898A4 (en) | 2010-10-29 | 2014-04-02 | Biogen Idec Inc | HETEROCYCLIC TYROSINE KINASE HEMMER |
WO2013185082A2 (en) | 2012-06-08 | 2013-12-12 | Biogen Idec Ma Inc. | Inhibitors of bruton's tyrosine kinase |
AR091273A1 (es) * | 2012-06-08 | 2015-01-21 | Biogen Idec Inc | Inhibidores de pirimidinil tirosina quinasa |
JP6431914B2 (ja) | 2013-12-11 | 2018-11-28 | バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. | 腫瘍学、神経学及び免疫学におけるヒト疾患の治療に有用なビアリール化合物 |
EP3444251B1 (en) | 2013-12-11 | 2023-06-07 | Biogen MA Inc. | Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology |
WO2016054627A1 (en) | 2014-10-03 | 2016-04-07 | Ohio State Innovation Foundation | Biomarkers of bruton tyrosine kinase inhibitor resistance |
-
2013
- 2013-06-05 AR ARP130101980 patent/AR091273A1/es not_active Application Discontinuation
- 2013-06-07 WO PCT/US2013/044800 patent/WO2013185084A1/en active Application Filing
- 2013-06-07 CN CN202110783143.4A patent/CN113549055A/zh active Pending
- 2013-06-07 BR BR122021002178-3A patent/BR122021002178B1/pt active IP Right Grant
- 2013-06-07 SG SG11201408173WA patent/SG11201408173WA/en unknown
- 2013-06-07 TW TW110102365A patent/TWI792158B/zh active
- 2013-06-07 KR KR1020227039393A patent/KR20220154850A/ko not_active Application Discontinuation
- 2013-06-07 EP EP13800042.7A patent/EP2858499B1/en active Active
- 2013-06-07 NZ NZ702715A patent/NZ702715A/en unknown
- 2013-06-07 KR KR1020157000393A patent/KR102102587B1/ko active IP Right Grant
- 2013-06-07 PL PL13800042T patent/PL2858499T3/pl unknown
- 2013-06-07 DK DK13800042.7T patent/DK2858499T3/en active
- 2013-06-07 CN CN201380036869.5A patent/CN104540385B/zh active Active
- 2013-06-07 EA EA201492056A patent/EA027823B1/ru unknown
- 2013-06-07 IN IN10576DEN2014 patent/IN2014DN10576A/en unknown
- 2013-06-07 ES ES13800042.7T patent/ES2684268T3/es active Active
- 2013-06-07 LT LTEP13800042.7T patent/LT2858499T/lt unknown
- 2013-06-07 TW TW102120447A patent/TWI592406B/zh active
- 2013-06-07 SG SG10201708535UA patent/SG10201708535UA/en unknown
- 2013-06-07 CA CA3108186A patent/CA3108186A1/en not_active Abandoned
- 2013-06-07 CN CN201810384098.3A patent/CN109305959B/zh active Active
- 2013-06-07 EP EP20186539.1A patent/EP3753934A1/en active Pending
- 2013-06-07 KR KR1020217017552A patent/KR102468430B1/ko active IP Right Grant
- 2013-06-07 JP JP2015516256A patent/JP6214643B2/ja active Active
- 2013-06-07 BR BR112014030655-9A patent/BR112014030655B1/pt active IP Right Grant
- 2013-06-07 PT PT13800042T patent/PT2858499T/pt unknown
- 2013-06-07 KR KR1020207010675A patent/KR20200043497A/ko active Application Filing
- 2013-06-07 SI SI201331130T patent/SI2858499T1/sl unknown
- 2013-06-07 EP EP18171833.9A patent/EP3385263B1/en active Active
- 2013-06-07 AU AU2013271407A patent/AU2013271407B2/en active Active
- 2013-06-07 CA CA2875799A patent/CA2875799C/en active Active
- 2013-06-07 TW TW106116775A patent/TWI719209B/zh active
- 2013-06-07 RS RS20180950A patent/RS57978B1/sr unknown
- 2013-06-07 EA EA201790418A patent/EA201790418A1/ru unknown
- 2013-06-07 US US14/406,315 patent/US9394277B2/en active Active
- 2013-06-07 HU HUE13800042A patent/HUE039897T2/hu unknown
- 2013-06-07 MX MX2014015044A patent/MX363672B/es unknown
- 2013-06-07 ES ES18171833T patent/ES2834333T3/es active Active
-
2014
- 2014-11-27 IL IL235938A patent/IL235938B/en active IP Right Grant
- 2014-12-03 PH PH12014502699A patent/PH12014502699B1/en unknown
- 2014-12-08 MX MX2019003618A patent/MX2019003618A/es unknown
- 2014-12-15 ZA ZA2014/09255A patent/ZA201409255B/en unknown
-
2015
- 2015-10-20 HK HK15110301.6A patent/HK1209284A1/xx unknown
-
2016
- 2016-06-29 US US15/196,389 patent/US9944622B2/en active Active
-
2017
- 2017-03-07 AU AU2017201536A patent/AU2017201536B2/en active Active
- 2017-08-03 JP JP2017150480A patent/JP2017193583A/ja not_active Withdrawn
-
2018
- 2018-03-05 US US15/911,546 patent/US10618887B2/en active Active
- 2018-07-09 PH PH12018501463A patent/PH12018501463A1/en unknown
- 2018-08-08 HR HRP20181294TT patent/HRP20181294T1/hr unknown
- 2018-08-16 CY CY181100861T patent/CY1120638T1/el unknown
-
2019
- 2019-02-04 JP JP2019017850A patent/JP2019077728A/ja not_active Withdrawn
- 2019-05-17 AU AU2019203476A patent/AU2019203476B2/en active Active
-
2020
- 2020-02-27 US US16/802,959 patent/US20210017155A1/en not_active Abandoned
- 2020-10-11 IL IL277951A patent/IL277951A/en unknown
-
2021
- 2021-02-08 JP JP2021018128A patent/JP2021073299A/ja active Pending
- 2021-02-08 JP JP2021018127A patent/JP2021073298A/ja active Pending
- 2021-04-21 AU AU2021202412A patent/AU2021202412A1/en not_active Abandoned
-
2022
- 2022-08-08 US US17/883,202 patent/US20230174511A1/en active Pending
- 2022-11-25 AU AU2022275504A patent/AU2022275504A1/en active Pending
-
2023
- 2023-01-16 JP JP2023004462A patent/JP2023052415A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2684268T3 (es) | Inhibidores de pirimidinil tirosina quinasa | |
ES2587738T3 (es) | Derivados de quinoxalina y quinolina como inhibidores de quinasa | |
ES2587903T3 (es) | Compuestos de imidazolidinadiona y sus usos | |
ES2585221T3 (es) | Un proceso para la preparación de 6-(7-((1-aminociclopropil)metoxi)-6-metoxiquinolin-4-iloxi)-n-metil-1-naftamida y productos intermedios sintéticos de la misma | |
BR112020006639A2 (pt) | processo estereosseletivo para a preparação de derivados policíclicos substituídos de piridona | |
US9593126B2 (en) | Synthesis of spirocyclic isoxazoline derivatives | |
ES2217833T3 (es) | Nuevos compuestos de piperazina y piperidina. | |
CA3009669A1 (en) | Bruton's tyrosine kinase inhibitors | |
ES2503794T3 (es) | Inhibidores de la actividad Akt | |
ES2617241T3 (es) | Derivados de triazol fusionados como moduladores de gama secretasa | |
AU2017364725B2 (en) | Method for producing triazolopyridine compound | |
EP3383875A1 (en) | 3-PYRIMIDINYL PYRROLO [2,3-b] PYRIDINE AS ANTICANCER AGENTS AND THE PROCESS FOR THE PREPARATION THEREOF | |
WO2006129626A1 (ja) | [1,2,4]トリアゾロ[1,5-c]ピリミジン誘導体の製造法 | |
ES2892161T3 (es) | Preparación de derivados de ácido 2-([1,2,3]triazol-2-il)-benzoico | |
JPS63145284A (ja) | イミダゾール誘導体およびその製法 | |
TW201725198A (zh) | 一種吡啶衍生物類化合物的製備方法及其中間體和晶型 | |
US9969735B2 (en) | Process for making tricyclic lactam compounds | |
US11939322B2 (en) | Method for producing tetracyclic compound | |
JP5130521B2 (ja) | 複素多環系フェナジン化合物 | |
ES2561879T3 (es) | Derivados de piridilbenzoxazina, composición farmacéutica que comprende los mismos y uso de los mismos | |
KR102204267B1 (ko) | 대체된 (r)-3-(4-메틸카바모일-3-플루오로페닐아미노)테트라하이드로퓨란-3-엔카르복실산(변이체) 및 이의 에스테르, 제조 방법 및 용도 | |
JP6997769B2 (ja) | 2-(6-ニトロピリジン-3-イル)-9H-ジピリド[2,3-b;3’,4’-d]ピロールの製造方法 | |
US20030191150A1 (en) | Process for producing tricyclic fused heterocyclic derivative | |
Kolyamshin et al. | Esters of 4-(3-Dialkylamino-2, 5-dioxo-2, 3, 4, 5-tetrahydro-1 H-pyrrolyl) phenylacetic acids | |
WO2023247666A1 (en) | Fluorescent probes for magl |